Aprea Therapeutics (APRE) News and press releases

Stocks That Hit 52-Week Lows On Wednesday

24 May 23

Options

On Wednesday, 129 stocks made new 52-week lows.

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

16 May 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 price target.

Aprea Therapeutics Q1 EPS $(1.34) Up From $(7.20) YoY

16 May 23

Earnings, News

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(1.34) per share. This is a 81.39 percent increase over losses of $(7.20) per share from the same period last year.

12 Health Care Stocks Moving In Friday's Pre-Market Session

7 Apr 23

Movers

Stocks That Hit 52-Week Lows On Monday

3 Apr 23

Options

On Monday, 76 companies set new 52-week lows.

Aprea Therapeutics Q4 EPS $(0.92) Beats $(2.60) Estimate

30 Mar 23

Earnings, News

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.92) per share which beat the analyst consensus estimate of $(2.60) by 64.62 percent. This is a 87.22 percent increase over losses of $(7.20) per share

Stocks That Hit 52-Week Lows On Monday

27 Mar 23

Options

On Monday, 89 stocks made new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

24 Mar 23

Options

On Friday, 469 companies hit new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023

10 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Maxim Group Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $16

10 Mar 23

News, Price Target, Initiation, Analyst Ratings

Maxim Group analyst Jason McCarthy initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $16.

Aprea Therapeutics to Present at BIO International Convention

30 May 23

News, Press Releases

DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

15 May 23

Earnings, Press Releases

DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

30 Mar 23

Earnings, Press Releases

DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based